The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

  title={The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug},
  author={Jon Cohen},
  • Jon Cohen
  • Published 27 October 2020
  • Political Science
  • Science
Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
The expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone are discussed from a clinical and pharmacovigilant point of view.
Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro
The benchmark results indicated that for docking calculations, Vina is more accurate than AD4, and for free energy methods, FEP is the most accurate method, followed by LIE, FPL, and MM-PBSA, and atomistic simulations revealed that the van der Waals interaction is the dominant factor.
Deceptive Communication
In cases of conflict of interest, people can lie directly about payoff relevant private information, or they can evade the truth without lying directly. We analyse this situation theoretically and
Design of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates
Modular, tunable autoproteolytic gene switches (TAGS) relying on synthetic transcription factors that self-inactivate, unless in the presence of coronavirus protease inhibitors, consequently activating transgene expression are described.
Essential Crimes? Essential Punishments? Rethinking Essentiality in the Midst of the COVID-19 Pandemic
This article sheds light on how the COVID-19 pandemic has helped illuminate just how essential these crimes and harms are to the perpetuation of the status quo by the powerful, and encourages us to consider which punishments are vital to a well-ordered society.
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?
Abstract After witnessing extraordinary scientific and regulatory efforts to speed development of and access to new COVID-19 interventions, patients facing other serious diseases have begun to ask
Identification and Development of Therapeutics for COVID-19
A range of approaches for the treatment of COVID-19 are described, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate.
Identification and Development of Therapeutics for COVID-19
How different modes of identifying candidate therapeutics have borne out during the COVID-19 pandemic is explored, providing important insight into how the ongoing pandemic can be managed and also demonstrates the power of interdisciplinary collaboration to rapidly understand a virus and match its characteristics with existing or novel pharmaceuticals.